GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 235 | 19 | 154 | 355 | 30 |
| TOTAL | $235 | $21 | $156 | $357 | $32 |
| Non-Current Assets | |||||
| PPE Net | 3 | 4 | 4 | 5 | 5 |
| TOTAL | $3 | $4 | $4 | $5 | $5 |
| Total Assets | $238 | $25 | $160 | $362 | $37 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 10,880 | 11,239 | 9,717 | 8,988 | 8,852 |
| Accounts payable and accrued liabilities | 2,061 | 2,100 | 1,814 | 1,574 | 1,538 |
| Accrued Expenses | 3,967 | 4,019 | 4,077 | 3,527 | 3,344 |
| Other current liabilities | 528 | 417 | 184 | 492 | 4,795 |
| TOTAL | $18,348 | $18,949 | $16,966 | $15,666 | $19,703 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 400 | 528 | 553 |
| TOTAL | $N/A | $N/A | $400 | $528 | $553 |
| Total Liabilities | $18,348 | $18,949 | $17,366 | $16,194 | $20,256 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 144,713 | 241 | 59 | 53 | 44 |
| Common Shares | 123 | N/A | 28 | 26 | 22 |
| Retained earnings | -126,964 | -124,649 | -121,820 | -118,190 | -119,734 |
| Other shareholders' equity | -166 | -166 | -166 | -166 | -166 |
| TOTAL | $-18,110 | $-18,924 | $-17,206 | $-15,832 | $-20,219 |
| Total Liabilities And Equity | $238 | $25 | $160 | $362 | $37 |